other material
confidence high
sentiment neutral
materiality 0.50
Corbus reports preliminary Q3 cash position of $104M as of Sep 30, 2025
Corbus Pharmaceuticals Holdings, Inc.
- Expected cash, cash equivalents, and investments of approximately $104.0 million.
- Includes $27.0 million in cash and cash equivalents.
- Figures are preliminary, subject to final closing procedures.
- No update on sales under Jefferies ATM agreement after September 30.